Stay updated on Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial
Sign up to get notified when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.

Latest updates to the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page
- Check3 days agoChange DetectedAdded a new MeSH term 'Primary interstitial lung disease specific to childhood' and a Genetic and Rare Diseases Information Center resources link to the study page.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check25 days agoChange DetectedRevision: v3.4.3 replaces the previous v3.4.2 on the page.SummaryDifference0.0%

- Check53 days agoChange DetectedRevision tag updated from v3.4.1 to v3.4.2.SummaryDifference0.0%

- Check60 days agoChange DetectedA minor revision tag was updated from v3.4.0 to v3.4.1; there is no evidence of substantive changes to study content or function. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check67 days agoChange DetectedAdded a 'Show glossary' option and updated metadata with Revision: v3.4.0, including capitalization changes to QC status labels. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.